tradingkey.logo
tradingkey.logo
Search

Lexeo Therapeutics Inc

LXEO
Add to Watchlist
4.480USD
-0.180-3.86%
Close 07-27 16:00ETQuotes delayed by 15 min
331.89MMarket Cap
LossP/E TTM

LXEO Income Statement

You can find the annual or quarterly income statement of Lexeo Therapeutics Inc here for insights into the performance and operational efficiency of Lexeo Therapeutics Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
Total revenue
----
----
----
----
----
----
----
----
----
--0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
--0.00
--531.00K
--37.00K
--85.55K
Revenue
----
----
----
----
----
----
----
----
----
--0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
--0.00
--531.00K
--37.00K
--85.55K
Operating expenses
-33.94%22.33M
-15.58%23.12M
-31.37%21.65M
30.31%30.69M
45.14%33.80M
82.86%27.38M
55.59%31.54M
68.52%23.55M
20.74%23.29M
-1.47%14.97M
12.55%20.27M
-8.95%13.97M
53.04%19.29M
--15.20M
--18.01M
--15.35M
--12.60M
R&D expenses
-8.55%15.70M
-11.74%16.21M
-32.99%15.70M
-11.11%14.72M
9.08%17.17M
123.70%18.37M
35.82%23.42M
47.38%16.56M
-4.23%15.74M
-27.90%8.21M
12.26%17.25M
-8.40%11.24M
62.01%16.44M
--11.39M
--15.36M
--12.27M
--10.15M
Depreciation, depletion, and amortization
-69.46%153.00K
-70.63%153.00K
-69.94%153.00K
-71.37%142.00K
5.25%501.00K
6.33%521.00K
10.65%509.00K
11.19%496.00K
6.50%476.00K
10.11%490.00K
34.50%460.00K
26.98%446.06K
6568.70%446.94K
--445.00K
--342.00K
--351.30K
--6.70K
Operating profit
33.94%-22.33M
15.58%-23.12M
31.37%-21.65M
-30.31%-30.69M
-45.14%-33.80M
-82.86%-27.38M
-55.59%-31.54M
-68.52%-23.55M
-20.74%-23.29M
1.47%-14.97M
-15.96%-20.27M
8.73%-13.97M
-54.09%-19.29M
---15.20M
---17.48M
---15.31M
---12.52M
Net non-operating interest income (expenses)
Non-operating interest income
75.79%2.11M
51.54%2.22M
-30.40%1.46M
-46.00%1.27M
-27.20%1.20M
32.94%1.47M
328.69%2.09M
297.97%2.35M
140.15%1.65M
63.02%1.10M
7.02%488.00K
233.33%590.00K
3877.87%687.50K
--676.00K
--456.00K
--177.00K
--17.28K
Non-operating interest expense
-54.05%17.00K
-10.00%27.00K
-37.14%22.00K
-28.57%25.00K
0.00%37.00K
-40.00%30.00K
-32.69%35.00K
-33.96%35.00K
-25.95%37.00K
-10.71%50.00K
79.31%52.00K
488.89%53.00K
--49.97K
--56.00K
--29.00K
--9.00K
--0.00
Gains from sale of securities
--42.00K
-121.74%-5.00K
--0.00
--3.39M
----
428.57%23.00K
----
----
-10.60%-5.00K
---7.00K
--1.00K
---3.00K
---4.52K
----
--0.00
----
----
Special income (expenses)
-2650.00%-330.00K
----
---60.00K
---34.00K
---12.00K
----
----
----
----
---258.00K
---272.00K
----
----
----
--0.00
----
----
Other non-operating income (expenses)
75.00%-1.00K
--9.00K
-200.00%-9.00K
-1300.00%-14.00K
---4.00K
--0.00
---3.00K
---1.00K
----
----
----
----
----
--0.00
----
--0.00
--146.00
Income before tax
38.16%-20.20M
19.31%-20.92M
31.22%-20.28M
-22.91%-26.10M
-50.61%-32.66M
-82.73%-25.92M
-46.65%-29.49M
-58.01%-21.24M
-16.21%-21.68M
2.68%-14.19M
-17.90%-20.11M
11.24%-13.44M
-49.24%-18.66M
---14.58M
---17.05M
---15.14M
---12.50M
Income tax
----
----
----
----
----
----
----
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Income after tax
38.16%-20.20M
19.31%-20.92M
31.22%-20.28M
-22.91%-26.10M
-50.61%-32.66M
-82.73%-25.92M
-46.65%-29.49M
-58.01%-21.24M
-16.21%-21.68M
2.68%-14.19M
-17.90%-20.11M
11.24%-13.44M
-49.24%-18.66M
---14.58M
---17.05M
---15.14M
---12.50M
Net income from continuous operations
38.16%-20.20M
19.31%-20.92M
31.22%-20.28M
-22.91%-26.10M
-50.61%-32.66M
-82.73%-25.92M
-46.65%-29.49M
-58.01%-21.24M
-16.21%-21.68M
2.68%-14.19M
-17.90%-20.11M
11.24%-13.44M
-49.24%-18.66M
---14.58M
---17.05M
---15.14M
---12.50M
Net income attributable to controlling interests
38.16%-20.20M
19.31%-20.92M
31.22%-20.28M
-22.91%-26.10M
-50.61%-32.66M
-82.73%-25.92M
-46.65%-29.49M
-58.01%-21.24M
-16.21%-21.68M
2.68%-14.19M
-17.90%-20.11M
11.24%-13.44M
-49.24%-18.66M
---14.58M
---17.05M
---15.14M
---12.50M
Net income attributable to common shareholders
38.16%-20.20M
19.31%-20.92M
31.22%-20.28M
-22.91%-26.10M
-50.61%-32.66M
-82.73%-25.92M
-46.65%-29.49M
-58.01%-21.24M
-16.21%-21.68M
2.68%-14.19M
-17.90%-20.11M
11.24%-13.44M
-49.24%-18.66M
---14.58M
---17.05M
---15.14M
---12.50M
Basic earnings per share
74.77%-0.25
65.15%-0.27
62.71%-0.33
6.91%-0.60
-27.26%-0.99
-36.24%-0.78
-9.42%-0.89
-18.11%-0.64
-2.46%-0.77
2.67%-0.58
-17.90%-0.82
11.24%-0.54
-49.24%-0.76
---0.59
---0.69
---0.61
---0.51
Diluted earnings per share
74.77%-0.25
65.15%-0.27
62.71%-0.33
6.91%-0.60
-27.26%-0.99
-36.24%-0.78
-9.42%-0.89
-18.11%-0.64
-2.46%-0.77
2.67%-0.58
-17.90%-0.82
11.24%-0.54
-49.24%-0.76
---0.59
---0.69
---0.61
---0.51
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Lexeo Therapeutics Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing LXEO stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Lexeo Therapeutics Inc's net income for the year?

Lexeo Therapeutics Inc posted -99.96M in net income for fiscal year 2025.

How much net income did Lexeo Therapeutics Inc post in the last quarter?

Lexeo Therapeutics Inc reported -20.20M in net income for the latest quarter。

What was Lexeo Therapeutics Inc's annual operating profit?

Lexeo Therapeutics Inc's operating income was -109.26M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.